Novo Nordisk said on Monday it is offering its diabetes drug Ozempic for $499 per month to eligible cash-paying type 2 ...

As the patent for semaglutide nears its end, Novo Nordisk's dominance in the weight-loss market is being challenged. The ...

Drugmaker Novo Nordisk received accelerated approval for the drug’s use in people with moderate to advanced liver scarring, ...

Novo Nordisk slashes Wegovy prices by 50% for cash-paying patients amid Trump's pressure on drugmakers to reduce costs.

GreensKeeper Asset Management, an investment management company, released its second-quarter 2025 investor letter. A copy of ...

Burke Wealth Management, an investment management company, released its “Focused Growth Strategy” second-quarter 2025 ...

Wegovy is now approved by FDA for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney ...

Days after it was announced that the cost of Mounjaro weight-loss jabs in the UK would treble in September, sales of Ozempic had surged by 600 per cent.

COMMENT: The monthly cost of a private prescription for Mounjaro is set to exceed £300 from next month – worrying news for ...

Through innovation, cost discipline, legal action, and competitive pricing, Novo Nordisk has reasserted its leadership in the GLP-1 market. With a robust pipeline and global expansion, NVO is poised ...

A Comeback Fueled by Resilience Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) has been a trailblazer in the GLP-1 drug ...